Annovis Bio, Inc

Annovis Bio (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company pioneering a new paradigm for treating chronic and acute neurodegenerative diseases — addressing one of the greatest unmet needs of our aging population: Alzheimer’s disease (AD) and Parkinson’s disease (PD). Our pipeline extends to other conditions driven by toxic protein accumulation, including traumatic brain injury (TBI), stroke, Down syndrome, Huntington’s disease, and certain neuropsychiatric disorders. Our lead investigational oral therapy, buntanetap, is a safe, once-daily pill designed to inhibit the overproduction of multiple neurotoxic proteins — including amyloid precursor protein (APP) and amyloid beta, tau, α-synuclein, and TDP-43 — through a unique RNA-targeted translational mechanism of action. By modulating protein synthesis upstream, buntanetap is designed to address the root biological drivers of neurodegeneration. Across 13 clinical studies involving more than 1,200 participants, buntanetap has consistently demonstrated a favorable safety profile, strong tolerability, and meaningful effects on cognitive improvement. In late-stage clinical development, buntanetap significantly improved cognitive function in patients with early Alzheimer’s and early Parkinson’s disease who also showed evidence of amyloid pathology. We are currently enrolling patients in our pivotal Phase 3 clinical trial in early Alzheimer’s disease in the United States and advancing additional clinical programs aimed at transforming the treatment landscape for neurodegenerative disorders.